AKT1 and nasopharyngeal carcinoma: miR-155 was found to target the PTEN-PI3K-AKT signaling pathway to promote the proliferation of nasopharyngeal carcinoma cells (NPC cells) and inhibit the apoptosis of NPC cells, which turned into a new target for the treatment of NPC [25].